期刊文献+

伊米配能在烧伤急性期的药代动力学研究 被引量:3

Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase.
原文传递
导出
摘要 目的 研究伊米配能 /西司他丁在烧伤急性期患者应用时的药代动力学特点。 方法  6名烧伤急性期患者 (P组 )第一次给药后 ,利用高效液相色谱分析技术测定其血浆、水疱液、痂下组织、尿液中伊米配能浓度 ,计算药代动力学参数 ;另选 10名健康志愿者为对照组 (C组 )。结果同C组相比 ,P组的药代动力学参数发生明显改变。表现为半衰期延长 :C组 (1.0 6± 0 .2 4)h、P组 (1.5 6±0 .5 5 )h ;分布容积增大 :C组 (13.96± 7.10 )、P组 (16 .16± 4.2 6 )。第一次给药后 1h即能测出P组水疱液和痂下组织中伊米配能浓度 ,分别为 (8.17± 1.6 9) μg/ml、(12 .14± 2 .72 ) μg/g。伊米配能的肾清除率与患者肌酐清除率呈正相关 (r =0 .5 834)。 结论 急性期应用负荷剂量的伊米配能 /西司他丁时应延长用药间隔时间 ;早期应用伊米配能 /西司他丁可穿透II度、III度烧伤组织 ; Objective To investigate the pharmacokinetic characteristics of lmipenem /cilastatin in burn patients during the acute phase. Methods Imipenem conentrations in the plasma,blister and,interstitial fluids and urine of 6 burn patients (P group) were determined during the acute phase by high performance liquid chromatography after the first initial dose.Pharmacokinetic parameters were thus produced and statistically analyzed by program package STAT 5.Ten healthy volunteers served as control group (C group). Results Compared to those in control group,pharmacokinetic parameters of Imipenem exhibited evident difference,such as prolonged half-life[(1.56±0.55)h vs (1.06±0.24)h ]and enlarged distributing volume(16.16±4.26)vs(13.96±7.10).Imipenem could be detected in the blister and interstitial fluids of burn patients 1 hr after the initial dose.Renal clearance of Imipenem was positively correlated to creatinine clearance(r=0.5834). Conclusion The intervals between doses should better be prolonged when loaded-dosage of lmipenem was administered in burn patients during the acute phase. Imipenem could penetrate Ⅱand Ⅲ degree burn wound when given in the acute phase.Attention should be paid to renal function when Imipenem was given.
出处 《中华烧伤杂志》 CAS CSCD 2000年第6期349-351,共3页 Chinese Journal of Burns
基金 全军"九五"指令性课题 !(96L0 42 )
关键词 烧伤 急性期 伊米配能 药物代谢动力学 抗生素 Imipenem/Cilastatin Pharmacokinetics Burn
  • 相关文献

参考文献1

  • 1A. Lesne-Hulin,P. Bourget,F. Ravat,C. Goudin,J. Latarjet. Clinical pharmacokinetics of ciprofloxacin in patients with major burns[J] 1999,European Journal of Clinical Pharmacology(7):515~519

同被引文献13

  • 1张小江,王辉,徐英春,谢秀丽,陈民钧.重症监护病房最常见革兰阴性杆菌的耐药变迁[J].中华医院感染学杂志,2004,14(10):1179-1182. 被引量:32
  • 2焦正,蒋新国,钟明康,陆伟跃.药物临床研究的计算机模拟[J].中国新药与临床杂志,2005,24(6):491-496. 被引量:13
  • 3史军.药物动力学和药效动力学在抗菌药物新药开发和临床治疗上的应用[J].中国临床药理学与治疗学,2007,12(2):121-133. 被引量:34
  • 4Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmaeokinetic/ pharmacodynamic (PK/PD) terminology for antiinfective drugs: an update[J]. J Antimicrob Chemother, 2005, 55 (5) : 601-607.
  • 5David CY. Computational Chemistry [M]. John Wiley & Sons, Inc. 2001.
  • 6Kuti JL, Nightingatle CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002[J]. Antimicrobial Agents and Chemotherapy, 2004,48 (7) : 2464-2470.
  • 7Frei RC, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic pharmacodynamie models with Monte Carlo simulation [J]. Journal of Antimicrobial Chemotherapy,2008,61(4):621-628.
  • 8Kuti JL, Horowita S, Nightingatle CH, et al. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem[J]. Pharmaeotherapy, 2005,25 (7) : 935-941.
  • 9Burgess DS, Frei CR. Comparison of β-lactam regimens for the treatment of Gramnegative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics [J]. Journal of Antimicrobial Chemotherapy, 2005, 56 (10): 893-898.
  • 10徐伟平.父母异体皮移植治疗小儿严重烧伤13例[J].中华整形烧伤外科杂志,1997,13:460-460.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部